Announced
Completed
Synopsis
Legend Biotech, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology, raised $150m in series A funding round. The investors include Hudson Bay Capital Management, Johnson & Johnson Innovation - JJDC, Lilly Asia Ventures, Vivo Capital, Smallcap World Funds, and RA Capital Management. Proceeds from the financing will be used to advance the research and development and commercialization of Legend’s pipeline programs and expansion of manufacturing facilities, enhancement of its research and development platform, as well as general corporate expenses.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.